> Forest Laboratories will take a $44.1 million charge on termination of its deal to co-promote the hypertension drug Azor with Daiichi Sankyo. Report
> GlaxoSmithKline launched its large-scale trials pitting Tykerb against Genentech's Herceptin in early-stage breast cancer. Tykerb report
> Worried that antipsychotics are prescribed when they're not needed, Washington State is working on a plan to ensure that the meds are used appropriately in children on Medicaid. Report
> Schering-Plough is getting the country's largest rooftop solar-energy system, according to PPL Renewable Energy, which is installing the panels at Schering's Summit, NJ, campus. Report
> Already a problem in Southeast Asia, counterfeit malaria drugs are flooding African areas already hard hit by the disease, according to a new study. Report
> Daiichi Sankyo posted a 24.3 percent increase in fiscal-year profits to $941.5 million, but revenues fell by 5.3 percent, and it expects smaller profits in the year to come. Report
> Solvay reported a slight rise in first-quarter rise sales and profits. Report
> Following Wal-Mart, Kroger expanded its popular $4 generic drug program. Report
> India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy report
> Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. Trimeris report
> Elixir Pharmaceuticals has dropped its bid for an $86 million IPO, saying that market conditions aren't right. At the same time, Aldagen, a small biotech company with 18 employees, is making a bid to raise $80 million in an IPO. IPO report
> Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Report
Emerging Drug Developer: Resolvyx Pharmaceuticals. Profile
And Finally... The Republic Party's new slogan sounds a little familiar to the folks marketing Effexor XR. Report